drugset / Trial / NCT07122609
Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma
NaSingle-groupOpen-labelTreatment
Summary
This is a prospective, single arm trial in patients with ≥ 18 years with relapsed and refractory DLBCL. Aim of this study is to evaluate the efficacy and safety of pirtobrutinib in combination with rituximab, gemcitabine, and oxaliplatin with or without polatuzumab vedotin (Pirto-R-GemOx±pola) in patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL) previously treated with covalent BTK inhibitors.
Timeline
- Start
- 2025-08-05
- Primary completion
- 2026-08-15
- Completion
- 2027-08-15
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Pirtobrutinib | Other / unclassified | 200 mg | — |
| Subject | Polatuzumab Vedotin | Other / unclassified | 1.8 mg/kg | Intravenous |
| Background | Gemcitabine | Small molecule | 1000 mg/m2 | — |
| Background | Oxaliplatin | Small molecule | 100 mg/m2 | — |
| Background | Rituximab | Monoclonal antibody | 375 mg/m2 | — |